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Abstract 
Background: Distraction osteogenesis for craniosynostosis is associated with significant 
hemorrhage. Additionally, patients usually require several transfusions. Tranexamic acid (TXA) is 
effective for reducing blood loss and the need for transfusions during surgeries. However, the 
significance of TXA infusion has not been thoroughly described yet. 
Methods: Forty-eight children undergoing distraction osteogenesis for craniosynostosis were 
administered intraoperative TXA infusion (loading dose of 10 mg/kg for 15 min, followed by 
continuous infusion at 5 mg/kg/h throughout surgery; n = 23) or normal saline (control, n = 25). 
Rotational thromboelastometry (ROTEMTM) was conducted to monitor changes in coagulation 
perioperatively.  
Results: Blood loss during surgery was significantly lower in the TXA-treated group than it was in 
the control group (81 vs. 116 mL/kg, P = 0.003). Furthermore, significantly fewer transfusions of red 
blood cells and fresh frozen plasma were required in the TXA group. In the control group, clotting 
time during the postoperative period was longer than it was during the preoperative period. 
Similarly, clot strength was weaker during the postoperative period. D-dimer levels dramatically 
increased in the control group compared with the TXA group after surgery. The duration of 
mechanical ventilation and the number of postoperative respiratory-related complications were 
significantly greater in the control group than they were in the TXA group. 
Conclusions: TXA infusion based on population pharmacokinetic analysis is effective in reducing 
blood loss and the need for transfusions during the surgical treatment of craniosynostosis. It can also 
prevent the increase in D-dimer levels without affecting systemic hemostasis. 
Key words: tranexamic acid; rotational thromboelastometry; craniosynostosis; transfusion 
Introduction 
Premature fusion of cranial sutures with 
resultant cranial distortion is termed craniosynostosis. 
The treatments for craniosynostosis are diverse, 
ranging from cranial molding helmet to distraction 
osteogenesis [1], which must be performed within one 
year of birth to allow the affected bones to be resolved 
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and regenerated without further defects [2]. 
Distraction osteogenesis is usually accompanied by 
relatively high blood loss and the subsequent need for 
blood transfusion in children aged < 1 year. 
Tranexamic acid (TXA) is a synthetic lysine 
analog that inhibits the proteolytic action of plasmin 
on fibrin clots and platelet receptors, thereby 
inhibiting fibrinolysis [3, 4]. It is efficient in reducing 
blood loss during surgery [5-8]. Currently, there are 
no concrete protocols for its use; however, there are 
reports on its population pharmacokinetics in 
different surgeries [5, 9, 10]. The hemostatic efficacy of 
TXA in children undergoing distraction osteogenesis 
has not been fully described. 
Rotational thromboelastometry (ROTEMTM) is 
used in the perioperative management of hemorrhage 
[11] and transfusion [12, 13]. It is effective in reducing 
the need for the transfusion of any allogenic blood 
product. Additionally, it is substantially cost-effective 
[14].  
The goals of this prospective, randomized, 
double-blind, placebo-controlled study were to 
evaluate the effects of TXA infusion based on its 
population pharmacokinetics by assessing blood loss 
and transfusion requirement in children undergoing 
distraction osteogenesis for craniosynostosis and to 
observe the impact of TXA on overall hemostasis by 
performing ROTEMTM analysis. 
Materials and Methods  
Study participants 
The study protocol was approved by the 
Institutional Review Board of the Severance Hospital 
of the Yonsei University Health System (Seoul, South 
Korea; IRB No. 4-2014-0274; June 3, 2014) and 
registered at http://clinicaltrials.gov (NCT02180321). 
Written informed consent was obtained from the 
parent or legal guardian of each patient. Fifty children 
who were scheduled for distraction osteogenesis for 
craniosynostosis were recruited in this study. 
Exclusion criteria were as follows: platelet count 
(PLT), < 50 × 103/μL; prothrombin time (PT) or 
activated partial thromboplastin time (aPTT) > 1.5 
times the reference value; history of convulsive 
seizure, epilepsy, or brain surgery; treatment with a 
non-steroidal anti-inflammatory agent within the 
previous 2 days; treatment with aspirin within 14 
days prior to surgery; and known allergy to TXA. 
Patients were evenly assigned to two groups (TXA or 
control) using computer-generated randomized 
tables. The group allocations were noted in 
sequentially numbered, sealed, and opaque 
envelopes. A research assistant who was not a study 
investigator opened the envelopes and prepared the 
infusions according to the group allocations. Besides 
the designated research assistant who prepared the 
study drugs, all study participants and care providers 
were blinded to the randomization. None of the 
patients received any antifibrinolytic agent prior to 
surgery. 
Management of anesthesia 
The following standardized general anesthesia 
protocol was used: induction with 2 mg/kg propofol 
and 1 μg/kg fentanyl, neuromuscular blockade with 
0.6 mg/kg rocuronium bromide, maintenance with 
desflurane or sevoflurane in an oxygen-air mixture 
(fraction of inspired oxygen, 0.5), and administration 
of intermittent bolus doses of fentanyl and 
rocuronium. A central venous catheter was placed in 
the femoral or internal jugular vein, whereas an 
arterial catheter was placed in the radial artery. Urine 
output was monitored using a urinary catheter. Rectal 
temperature was measured and maintained at 
normothermic levels with a forced-air blanket 
throughout the surgery. TXA was administered as an 
intravenous loading dose of 10 mg/kg over 15 min, 
followed by continuous intravenous infusion at 5 
mg/kg/h from the beginning of the surgery until skin 
closure [5]. Normal saline was similarly administered 
throughout the surgery to the control group.  
Transfusion strategies  
The need for perioperative transfusion was 
determined according to the transfusion guidelines 
and agreement by both the surgical and anesthesia 
care teams [11, 15] as follows: packed red blood cells 
(RBC) transfusion in response to early clinical signs of 
circulatory shock, significant decrease in blood 
pressure with a hematocrit (Hct) < 30%, acute 
intraoperative blood loss ≥ 15% of estimated blood 
volume (EBV), Hct < 24% with signs of anemia, and 
clinical coagulopathy requiring hemostatic blood 
product transfusion (PLT < 50 × 103/μL or internat-
ional normalized ratio > 2 times the reference value) 
with either excessive microvascular bleeding or active 
bleeding [11, 16]. Blood products were filtered and 
irradiated prior to transfusion.  
Hemoglobin/Hct, PLT, PT, and aPTT were 
determined before the study drugs were 
administered, serially at every 60 min during surgery, 
at the end of the surgery, and on postoperative days 1 
and 2. The levels of fibrinogen and D-dimer were 
measured before the study drugs were administered 
and at the end of the surgery.  
Distraction osteogenesis 
All the patients underwent distraction 
osteogenesis to correct cranial deformities. Osteotomy 
was performed according to the relevant design for 
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the specific diagnosis of craniosynostosis. After 
successful osteotomy and bone flap elevation, 
distraction devices (Jeil Medical Corp., Seoul, 
Republic of Korea) were fixed. The number of 
distraction devices required was determined based on 
the type of osteotomy [1, 17]. Patients were monitored 
in the neurosurgical intensive care unit for 1–2 days 
after surgery.  
Outcome measures 
Due to the inaccuracy in estimating blood loss 
during surgery, blood loss was calculated by the 
anesthesiologist using a previously adopted formula 
for this patient population [6, 18, 19]:  
 Estimated red cell volume (ERCV)lost = ERCVpreoperative 
+ ERCVtransfused – ERCVpostoperative 
where ERCV is EBV × Hct/100.  
EBV is 80 mL/kg for infants younger than 12 
months and 75 mL/kg for children older than 12 
months. ERCVtransfused was calculated as follows:  
ERCVtransfused = transfused volume of packed RBC 
(mL) × Hct of packed RBC/100 
Hct of packed RBC was estimated to be 
approximately 60% by the local blood bank. 
Therefore, EBVlost was calculated as: 
EBVlost (mL/kg) = ERCVlost (mL)/[Weight (kg) × 
Hctpreoperative/100] 
Routine fluid management during surgery 
consisted of continuous administration of balanced 
crystalloid with additional SD 1:4 solution (0.2% NaCl 
with dextrose). The amount of fluid administered was 
determined based on preoperative fasting time, 
intraoperative deficits, and basal fluid maintenance. 
Colloid [hydroxyethyl starch (6%, 130/0.4) in a 
balanced electrolyte solution, Volulyte; Fresenius 
Kabi, Schelle, Belgium] up to 20 mL/kg/day was 
administered in case of acute and massive 
perioperative blood loss prior to the initiation of 
blood product preparation and transfusion. 
Controlled hypotension was not performed during 
surgery. The scalp was infiltrated with local 
anesthetics containing epinephrine during the 
surgical procedure. 
ROTEMTM analyses were performed three times 
during the study period: prior to administration of the 
study drugs (T0), immediately after surgery (T1), and 
24 h after surgery (T2). Blood samples for ROTEMTM 
analyses were drawn from an indwelling arterial 
catheter. Clot formation, propagation, and strength 
were evaluated extrinsically (EXTEM, extrinsically 
activated test with tissue factor) and intrinsically 
(INTEM, intrinsically activated test using ellagic acid). 
In addition, an extrinsically activated test was 
performed using the platelet-blocking substance 
cytochalasin D (FIBTEM, fibrin-based extrinsically 
activated test with tissue factor and the platelet 
inhibitor cytochalasin D) for the separate evaluation 
of functional fibrin polymerization without platelet 
activity. All ROTEMTM analyses were performed 
according to standard protocols with a minimum 
running time of 60 min by a designated experienced 
anesthesiologist (JWL). 
During regular postoperative follow-ups, the 
patients were examined for any clinical evidence of 
TXA-related adverse events, such as clinically evident 
thromboembolic or neurologic events, until 3 months 
after the surgery. 
Statistical analysis 
The primary objective of this study was to 
compare blood loss and transfusion requirement 
between the TXA and control groups. The secondary 
objective was to evaluate the hemostatic effect of TXA 
by performing ROTEMTM analyses. For a statistical 
power of 0.80, a group size of at least 23 was obtained 
from calculations to detect a large effect size of 0.85 by 
using a two-tailed test (α = 0.05) [6]. Considering 
potential dropout rates, investigators decided to 
enroll 25 patients per group. Data are presented as 
mean ± standard deviation or median (interquartile 
range) for continuous variables based on the 
Kolmogorov–Smirnov normality test or number of 
patients (percentage) for categorical variables. 
Student’s t-test or Mann–Whitney U-test was used 
depending on the underlying distribution to detect 
differences in results between the TXA and control 
groups. Repeatedly measured variables, such as 
hemoglobin/Hct, PLT, PT, and aPTT were analyzed 
using linear mixed models with Bonferroni correction. 
Statistical analyses were performed using SPSS for 
Windows (version 23.0; SPSS Inc., Chicago, IL, USA). 
P < 0.05 was considered statistically significant. 
Results 
Fifty patients, aged 4 months to 5 years, were 
enrolled in the study from July 2014 to March 2016. 
Two patients in the TXA group were excluded from 
the analysis because of an error in the ROTEMTM 
analysis. Patient demographics and surgery-related 
data were comparable between the two groups (Table 
1). 
Intraoperative blood loss was significantly lower 
in the TXA group than it was in the control group (81 
vs. 116 mL/kg; P = 0.003). Although the same 
transfusion guidelines were followed for both groups, 
the amount of blood products administered 
intraoperatively was significantly lower in the TXA 
group than it was in the control group [packed RBC, 
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49 vs. 65 mL/kg, P = 0.010; fresh frozen plasma (FFP), 
19 vs. 28 mL/kg, P = 0.038]. Moreover, no patient in 
the TXA group was administered a blood product 
postoperatively, except for two patients who were 
administered FFP on postoperative day 1 (Table 2). 
The amount of crystalloid administered during 
surgery was comparable between the two groups; 
however, a significantly smaller volume of colloids 
was administered intraoperatively in the TXA group 
than in the control group (17 vs. 20 mL/kg, P = 0.026). 
Although the number of patients treated with 
diuretics and the amount of diuretics administered 
perioperatively were comparable between the two 
groups (data not shown), urine output was lower in 
the TXA group than it was the control group on 
postoperative day 1 (59.4 vs. 80.0 mL/kg, P = 0.010; 
Table 2). 
 
Table 1. Patient Characteristics and Surgery-related Data. 
 TXA (n=23) Control 
(n=25) 
P-value 
Age (months) 12 (7-22) 14 (8-30) 0.380 
Male, n (%) 14 (61) 10 (40) 0.153 
Height (cm) 76.7 ± 8.1 80.0 ± 11.4 0.256 
Weight (kg) 10.1 ± 2.3 10.7 ± 2.6 0.430 
Preoperative Medical Problem, n 
(%)* 
11 (48) 13 (52) 0.775 
Concomitant Features, n (%)** 6 (26) 8 (32) 0.656 
Diagnosis, n (%)    
  Sagittal 8 (35) 7 (28) 0.616 
  Metopic 2 (9) 0 (0) 0.136 
  Unilateral coronal 5 (22) 2 (8) 0.182 
  Bilateral coronal 2 (9) 3 (12) 0.711 
  Lambdoid 2 (9) 3 (12) 0.711 
  Multiple  4 (17) 10 (40) 0.088 
Duration of Surgery (min) 264.0 ± 75.1 262.6 ± 48.4 0.939 
Duration of Anesthesia (min) 326.1 ± 58.4 352.4 ± 45.3 0.086 
Values are mean ± standard deviation, median (interquartile range), or number of 
patients (percentage). 
TXA: tranexamic acid; ASA: American Society of Anesthesiology physical status 
classification. 
* Preoperative medical problems: Abnormal electrocardiogram, abnormal chest 
x-ray, mildly increased serum liver enzyme levels (aspartate aminotransferase and 
alanine aminotransferase) 
**Concomitant features: Structural heart disease, hypothyroidism, hydrocephalus, 
diagnosed with Crouzon, Apert syndrome, Chiari malformation. 
 
Preoperative baseline Hct, PLT, fibrinogen level, 
PT, aPTT, and D-dimer level did not differ 
significantly between the two groups. However, Hct 
was significantly higher in the TXA group than it was 
in the control group at the end of surgery and on 
postoperative day 2 [32 vs. 29% (P = 0.048) and 35 vs. 
30% (P = 0.034), respectively]. Similarly, PLT was 
significantly higher in the TXA group on 
postoperative day 2 (267 vs. 194 × 103/μL, P = 0.010; 
Fig. 1A and 1B, respectively). Postoperative aPTT at 
the end of surgery was significantly longer in the 
control group than it was in the TXA group (36 vs. 41 
s, P = 0.028; Fig. 1D). Furthermore, D-dimer level 
dramatically increased after surgery in the control 
group; however, the increase in D-dimer level was 
suppressed in the TXA group (Fig. 1F). Compared 
with preoperative baseline values, PT was 
significantly prolonged and fibrinogen level was 
significantly reduced after surgery in both groups 
(Fig. 1C and 1E); however, these parameters were 
comparable between the two groups. 
 
Table 2. Perioperative Fluid Management Between Groups. 
  TXA 
(n=23) 
Control 
(n=25) 
P-value 
Intraoperative 
period 
Input    
 Crystalloid (mL/kg) 35.5 (26.1-41.2) 29.1 (21.7-38.2) 0.151 
 Colloid (mL/kg) 16.7 (14.1-20.0) 20.0 (16.7-20.0) 0.038 
 Packed RBC (mL/kg) 48.8 ± 16.8 65.2 ± 24.2 0.010 
 FFP (mL/kg) 19.4 ± 13.0 28.1 ± 15.1 0.038 
 platelet concentrate 
(mL/kg) 
5.9 (0-12.9) 10 (2.1-16.9) 0.217 
Number of patients receiving transfusion  
 Packed RBC  23 (100) 25 (100) > 0.999 
 FFP  23 (100) 25 (100) > 0.999 
 platelet concentrate  14 (61) 20 (80) 0.149 
Output    
 Blood loss (mL/kg) 80.6 ± 33.3 115.6 ± 43.6 0.003 
 Urine Output (mL/kg) 29.8 (18.2-33.8) 29.8 (18.7-43.3) 0.828 
Postoperative  
day 1 
Input    
 Crystalloid (mL/kg) 78.5 ± 23.1 83.1 ± 29.8 0.557 
 Colloid (mL/kg) - -  
 Packed RBC (mL/kg) - 0 (0-7.4) 0.003 
 FFP (mL/kg) 0 (0-0) 0 (0-0) > 0.999 
 platelet concentrate 
(mL/kg) 
- 0 (0-0) 0.090 
Number of patients receiving transfusion 
Packed RBC 0 8 (32) 0.003 
FFP 2 (9) 2 (8) >.999 
PLT 0 3 (12) 0.090 
Output    
 Blood loss (mL/kg) 5.3 (3.4-8.0) 4.1 (2.3-7.2) 0.252 
 Urine Output (mL/kg) 59.4 (48.4-67.0) 80.0 (54.0-95.6) 0.010 
Postoperative  
day 2 
Input    
 Crystalloid (mL/kg) 57.4 (44.4-64.5) 54.1 (48.0-74.3) 0.570 
 Colloid (mL/kg) - -  
 Packed RBC (mL/kg) - 0 (0-0) 0.025 
 FFP (mL/kg) - 0 (0-0) 0.337 
 platelet concentrate 
(mL/kg) 
- - > 0.999 
Number of patients receiving transfusion  
 Packed RBC  0 5 (20) 0.025 
 FFP  0 1 (4) 0.337 
 platelet concentrate  0 0 > 0.999 
Output    
 Blood loss (mL/kg) 1.3 (0.8-2.1) 1.3 (0.9-2.1) 0.926 
 Urine Output (mL/kg) 64.6 (56.5-83.0) 66.9 (46.3-94.6) 0.703 
Values are mean ± standard deviation, median (interquartile range), or number of 
patients (percentage). TXA: tranexamic acid; OR: odds ratio; packed RBC: packed 
red blood cells; FFP: fresh frozen plasma. 
 
ROTEMTM analyses showed no significant 
differences in EXTEM, INTEM, or FIBTEM between 
the two groups (Fig. 2); however, differences in some 
ROTEMTM data were significant when preoperative 
baseline values were compared with the respective 
values at the end of surgery. For EXTEM, initiation 
and propagation of clot formation were delayed at the 
end of surgery in the control group. In addition, clot 
strength, which is based on clot amplitude at 10 min 
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after clotting time (A10) and maximum clot firmness 
(MCF), reduced in both groups (Fig. 2A-D). For 
INTEM, prolonged clot propagation, decreased clot 
strength, increased clot formation time (CFT), and 
decreased A10 and MCF were observed at the end of 
surgery in both groups (Fig. 2E-H). Furthermore, lysis 
index at 30 min (percentage of clot firmness remaining 
after 30 min in relation to MCF), lysis onset time 
(defined as the time needed for clot firmness to 
decrease by 15% of MCF), and maximum clot lysis 
were determined to assess the degree of fibrinolysis. 
No intergroup differences were noted in the lysis 
parameters. Changes in INTEM and EXTEM 
parameters from the preoperative baseline values 
were not observed on postoperative day 1. Although 
fibrinogen levels significantly reduced in both groups, 
clot strength, based on the results of the FIBTEM 
analysis, significantly reduced only in the control 
group after surgery (Fig. 2I and 2J). 
Mechanical ventilation time, which indicates the 
total duration of mechanical ventilation applied 
during the intraoperative and postoperative periods, 
was significantly shorter in the TXA group than it was 
in the control group (327 vs. 378 min, P = 0.024; Table 
3). The number of patients with postoperative 
complications, such as pulmonary edema, 
pneumonia, and transfusion-related acute lung injury, 
was significantly higher in the control group than it 
was in the TXA group (0 vs. 4 [16%], P = 0.047). The 
total lengths of postoperative stay in the 
neurovascular care unit and the hospital were 
comparable between the two groups (Table 3). There 
was no incidence of convulsive seizure or a 
thromboembolic event in any patient during the 
study. 
 
 
Figure 1. Changes in (A) hematocrit, (B) platelet count, (C) prothrombin time, (D) activated partial thromboplastin time, (E) fibrinogen level, and (F) D-dimer level 
over time in patients undergoing distraction osteogenesis for craniosynostosis between the TXA (solid lines) and control (dotted lines) groups. Values represent the 
mean, and error bars represent the standard deviation. *P < 0.05 vs. baseline in the TXA group; †P < 0.05 vs. baseline in the control group; ‡P < 0.05 between the two 
groups. TXA: tranexamic acid; POD: postoperative day; preop: preoperative period; op end: at the end of surgery. 
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Figure 2. Changes in (A, E) CT of INTEM and EXTEM; (B, F) CFT of INTEM and EXTEM; (C, G, I) A10 of INTEM, EXTEM, and FIBTEM; (D, H, J) MCF of INTEM, 
EXTEM, and FIBTEM over time in patients undergoing distraction osteogenesis for craniosynostosis between the TXA (solid lines) and control (dotted lines) groups. 
Values represent the mean, and error bars represent standard deviation. *P < 0.05 vs. baseline in the TXA group; †P < 0.05 vs. baseline in the control group. TXA: 
tranexamic acid; POD: postoperative day; preop: preoperative period; op end: at the end of surgery; CT: clotting time; EXTEM: extrinsically activated test; INTEM: 
intrinsically activated test; FIBTEM: fibrin-based extrinsically activated test; A10: clot amplitude at 10 min after clotting time; MCF: maximum clot firmness; CFT: clot 
formation time; APTEM: extrinsically activated test containing aprotinin. 
 
 
Table 3. Postoperative Outcomes. 
 TXA 
(n=23) 
Control 
(n=25) 
Estimated 
Treatment Effect 
P- 
value 
NCU stay (h) 20 (19-21.5) 22 (19-24.5) -1.0 [-3.0 to 0.5] 0.141 
Mechanical 
ventilation time (min)* 
326.5 ± 65.8 377.7 ± 84.5 51.2 [-95.4 to -6.9] 0.024 
Complications, n(%)** 0 (0) 4 (16) 0.48 [0.35 to 0.65] 0.047 
Hospital stay (days) 10.1 ± 3.6 10.9 ± 5.1 0.8 [-3.4 to 1.8] 0.542 
Values are mean ± standard deviation, median (interquartile range), or number of 
patients (percentage). Estimated treatment effect is presented as mean difference 
[95% confidence interval] or relative risk [95% confidence interval]. 
TXA: tranexamic acid; NCU: neurovascular care unit. 
* Total duration of mechanical ventilation applied during intraoperative and 
postoperative periods.  
** Any event of pulmonary edema, pneumonia, or transfusion-related acute lung 
injury. 
 
Discussion 
TXA administration based on dosing schemes 
derived from population pharmacokinetic analyses 
was shown to reduce blood loss and transfusion 
requirement. Although ROTEMTM analysis failed to 
show TXA-induced changes in systemic hemostasis, it 
indicated significant changes in D-dimer levels. 
Furthermore, changes in FIBTEM indicated the 
preserved quality of fibrin-based clot at the end of 
surgery with subsequent hemostatic functional 
benefit following TXA administration [20-23]. 
The efficacy of TXA in reducing blood loss may 
differ depending on its plasma level [24, 25]. A 
previous pharmacokinetic study showed that 
systemic clearance of TXA was significantly reduced 
in patients weighing ≤ 10 kg or aged ≤ 12 months. This 
suggests that caution should be taken when 
administering TXA to such patients, especially those 
scheduled for surgeries that result in massive 
bleeding and/or high transfusion requirement [5]. 
The results of recent investigations on the population 
pharmacokinetics of TXA have aided the 
development of a more precise protocol for TXA 
administration to pediatric patients [5, 9, 10].  
TXA-induced hemostasis involves inhibition of 
plasminogen-plasmin interactions on the surface of 
fibrin, thereby preventing fibrin degradation [3]. 
D-dimer is a protein product of cross-linked fibrin 
degradation, whose level in the blood elevates during 
hyperfibrinolysis and massive hemorrhage caused by 
fibrinolysis [26, 27]. D-dimer level had also shown 
clinical significance as a predictor of patient morbidity 
and transfusion requirement [29]. Although D-dimer 
could not be considered the gold standard measure of 
fibrinolysis, several studies had reported the 
antifibrinolytic effect of TXA related to blood loss and 
the changes in the levels of fibrinolysis markers, such 
as D-dimer, in various types of surgeries [28, 30]. The 
suppressed increase in D-dimer level in the TXA 
group during the postoperative period observed in 
this study could be due to the antifibrinolytic action of 
TXA (Fig. 1F). 
The antifibrinolytic activity of TXA resulted in 
reduced transfusion requirement until postoperative 
day 2 in this study. Although the mean half-life of 
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TXA is 120 min [31], its hemostatic effect in patients, 
including children undergoing surgery for 
craniosynostosis treatment, can extend up to 24 h after 
it is discontinued [3, 6, 32]. This is considered as a 
residual effect at the surgical site, rather than a 
systemic effect [6, 33, 34]. However, despite the 
long-term effect of TXA in reducing the amount of 
transfusion required, no statistically significant 
difference was found between the two groups 
regarding the amount of blood lost during the 
postoperative period. Such lack of statistical 
significance may be attributed to the excessive 
hemorrhage in both groups, regardless of TXA 
administration. Although TXA effectively reduced 
intraoperative hemorrhage, the extent of blood loss 
(average, > 80 mL/kg) was equivalent to the total 
blood volume of an average 1-year-old child weighing 
approximately 10 kg. The observed dramatic drop in 
PLT and fibrinogen level after surgery could have 
been caused by the massive hemorrhage. 
ROTEMTM analysis was performed before and 
after surgery to evaluate the changes in overall 
coagulation status. Prolonged CFT and a substantial 
drop in A10 and MCF in the EXTEM test at the end of 
surgery were attributed, in part, to decreased PLT and 
fibrinogen level from their respective baseline values 
in both groups. Significant blood loss was treated 
with packed RBC and FFP transfusions in the control 
group, which could have contributed to the reduced 
PLT and fibrinogen level. Consequently, no 
significant differences in the results of the ROTEMTM 
analysis were found between the two groups. In the 
control group, FIBTEM A10 and MCF, which are 
indicative of clot strength and fibrinogen activity, 
significantly reduced compared to their respective 
baseline values (Fig. 2I and 2J). This might have been 
due to a dilution effect caused by the significantly 
large amount of FFP transfused during surgery. 
Therefore, transfusing more concentrated fibrinogen 
supplements, such as cryoprecipitates, may be a better 
option when treating children with a smaller 
circulation volume. Moreover, although it had been 
restricted to 20 mL/kg/day, the significantly large 
amount of colloid as a volume expander prior to 
transfusion in the case of acute and massive 
perioperative bleeding, may have affected the 
coagulation status and interfered with the ROTEMTM 
analysis. Colloids enhance fibrinolysis by diminishing 
α2-antiplasmin-plasmin interactions [35], thereby 
impeding fibrin formation and reducing 
fibrinogen-dependent clot strength [36, 37]. Although 
clinical data on the safe use of colloids in children are 
insufficient, some studies have shown that colloid 
infusions do not affect renal and coagulation systems 
in children [38, 39]. One noticeable benefit of TXA 
during surgery is the decreased incidence of 
postoperative respiratory-related complications. 
Transfusion of packed RBC (> 60 mL/kg) and/or 
hemostatic products, such as FFP, platelet 
concentrates, and cryoprecipitates, was found to be an 
independent predictor of the occurrence of 
postoperative cardiorespiratory and hematological 
events [40]. The substantial number of transfusions 
received by patients in the control group may have 
prolonged mechanical ventilation time and resulted in 
a higher probability of respiratory-related complica-
tions (Table 3). 
This study has several limitations. First, only 
packed RBC, FFP, and platelet concentrates were 
transfused due to the limited clinical availability of 
fibrinogen and cryoprecipitates. Second, the study 
design had limited the use of ROTEMTM analyses as 
the reference values for data interpretation, rather 
than the transfusion guidelines. Thirdly, in addition 
to EXTEM, INTEM, and FIBTEM, APTEM 
(extrinsically activated test containing aprotinin) 
could have been performed to enrich hemolytic 
profiles. This is because APTEM is useful when 
predicting the effects of antifibrinolytic agents on 
hyperfibrinolysis [41]. Moreover, randomized studies 
with a greater number of patients will be required to 
further investigate the discrepancy between the 
changes in the amount of blood loss and transfusion 
requirement and ROTEMTM analysis, especially with 
lysis parameters.  
In conclusion, results of this study show that 
TXA administration based on the dosage regimen 
predicted from population pharmacokinetic analysis 
can be effective in reducing blood loss and transfusion 
requirement in pediatric patients undergoing distrac-
tion osteogenesis for craniosynostosis. Furthermore, 
the effects of antifibrinolytic agents on systemic 
hemostasis must be investigated in viscoelastic 
studies.  
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